ArticleCancer medicine2025
Pretreatment Amide Proton Transfer-Weighted Imaging Histogram Analysis Combined With ER-Negative and HER2-Positive Expression Predicts Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo evaluate the predictive value of pre-treatment histogram analysis using APTWI, diffusion-weighted imaging (DWI), and early contrast-enhanced silhouette imaging in determining pathological complete response (pCR) post-NAC in breast cancer, and to investigate whether combining immunohistochemical indicators enhances predictive accuracy. MATERIALS AND
methodsA retrospective continuous collection of 108 females with breast cancer who underwent NAC and pre-treatment APTWI, DWI, and dynamic contrast-enhanced imaging at our hospital. Clinical, MRI imaging, and pathological characteristics were analyzed for patients. NAC response was divided into pCR and non-pCR. Tumor segmentation and histogram feature extraction were performed on APT, ADC, and early contrast-enhanced silhouette images, and combined them with clinical features to construct an NAC efficacy prediction model. Diagnostic performance was assessed using receiver operating characteristic curves, with DeLong's test employed to compare areas under the curve (AUC).
resultsIn pCR group, mean, root-mean-square deviation, and 5th, 10th, 15th, 25th, 50th, 75th, 85th percentile of MTRasym, along with 1st percentiles of ADC were significantly higher in the pCR group than in the non-pCR group (p < 0.05). Conversely, the interquartile range of MTRasym and 10th percentiles of ADC were significantly lower in the pCR group (p < 0.05). ER-negative, HER2-positive expression, and 5th percentile MTRasym value were identified as independent predictors of pCR post-NAC (odds ratios, 0.16, 7.25, and 1.35, respectively). The combined diagnostic model demonstrated an AUC of 0.844, significantly outperforming individual parameters (p < 0.05).
conclusionPre-treatment histogram analysis of MTRasym values derived from APTWI provides significant predictive value for pCR post-NAC in breast cancer. The combined diagnostic model incorporating APTWI with ER and HER2 expression status further enhances diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.